Prothena Corp (PRTA)

• Market cap: $568M
• 1 day: 4.76%
• 5 days: -1.86%
• 1 month: 3.83%
• 3 months: 36.79%
• 6 months: 44.86%
• Year to date: -22.75%
• 1 year: -39.62%
• 5 years: -13.37%
• 10 years: -82.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Employees: 163